# About Carolina Peptide — An Independent Tissue-Repair Research Desk

> About Carolina Peptide: an independent literature digest on three Recovery & Tissue Repair research peptides. How it is compiled, what it covers, and what it is not — not a seller, not a clinic, not medical advice.

An independent, citation-anchored digest of the soft-tissue and connective-tissue repair literature. Not a vendor. Not a clinic. Not medical advice.

## What Carolina Peptide is

Carolina Peptide is an independent editorial desk covering three research peptides organized around **soft-tissue and connective-tissue repair**: GLOW (a three-peptide combination), KPV (a gut-focused anti-inflammatory tripeptide), and TB-500 (an actin-binding fragment of thymosin beta-4), with TB-500 as the lead compound. Each has its own page; a comparison page reads them side by side across mechanism, evidence depth, and regulatory status; and a single shared reference list aggregates every citation used across all three.

The organizing discipline here is quantitative wherever the literature allows it: species and sample size, dose or dose-range, and effect size — a percentage, a hazard figure, an mg/kg — rather than adjectives. Where a finding rests on 40 human volunteers and where it rests on a single mouse-colitis model are two very different evidentiary positions, and this desk states which is which every time.

## How it is compiled

Two rules govern this desk. First, every factual claim traces to a numbered citation — peer-reviewed, PubMed-indexed literature with a DOI or PubMed link, gathered on the [references page](/references). Findings drawn from a review article rather than a primary study are labeled as such. Second, evidence is reported at the strength it was actually measured, not the strength marketing language implies: a Phase 1 safety trial in 40 healthy volunteers is described as exactly that, not extrapolated into a claim about efficacy; a combination product like GLOW is described as having zero blend-level trials, even though its individual ingredients are separately well studied. Where a fragment-versus-full-protein distinction complicates a claim — as it does throughout the TB-500 literature — this desk states the complication rather than smoothing over it.

## What it is not

Carolina Peptide is not a pharmacy, clinic, or vendor of any kind. It does not sell, source, or broker GLOW, KPV, TB-500, or any of their constituents, and has no affiliate relationship with any research-chemical supplier. It does not recommend a dose, a schedule, or a route of administration for any person, and none of the compounds discussed here is FDA-approved for human use. Two of the three peptides discussed — TB-500 directly, and GLOW through it — are prohibited in tested competitive sport. Readers with a specific medical question should consult a licensed clinician. Editorial corrections — an outdated citation, a newly published trial — can be sent via the [contact page](/contact); this desk reads that correspondence carefully and cannot respond to requests for medical advice.

---

A data-first ledger of tissue-repair peptide research — effect sizes and citations, not a clinic or a shop.